Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Introduction: The utility of Cytokeratin-18 fragment, namely CK18Asp396 (M30), for the diagnosis of non-alcoholic steatohepatitis (NASH) is currently uncertain. We aimed to provide further data in this area among multi-ethnic Asian subjects with NAFLD.
Materials and Methods: The accuracy of M30 for detecting NASH was compared with serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT) levels in consecutive adult subjects with biopsy-proven non-alcoholic fatty liver disease (NAFLD).
Results: Data for 93 NAFLD subjects (mean age 51.0 ± 11.1 years old and 51.6% males) and 20 healthy controls (mean age 50.2 ± 16.4 years old and 33.3% males) were analyzed. There were 39 NASH subjects (41.9%) and 54 non-NASH subjects (58.1%) among the NAFLD subjects. Plasma M30 (349 U/L vs. 162 U/L), and serum ALT (70 IU/L vs. 26 IU/L), AST (41 IU/L vs. 20 IU/L) and GGT (75 IU/L vs. 33 IU/L) were significantly higher in NAFLD subjects than in healthy controls. Serum ALT (86 IU/L vs. 61 IU/L), AST (58 IU/L vs. 34 IU/L) and GGT (97 IU/L vs. 56 IU/L) were significantly higher in NASH subjects compared to non-NASH subjects, but no significant difference was observed with plasma M30 (435 U/L vs. 331 U/L). The accuracy of plasma M30, and serum ALT, AST and GGT was good for predicting NAFLD (AUROC 0.91, 0.95, 0.87 and 0.85, respectively) but less so for NASH (AUROC 0.59, 0.64, 0.75 and 0.68, respectively). Serum ALT and AST, but not plasma M30 showed a significant trend with increasing grades of ballooning and lobular inflammation.
Conclusion: The utility of M30 in the detection of NASH in clinical practice appears limited, in comparison to routine biochemical markers.
- References:
J Hepatol. 1986;2(2):165-73. (PMID: 3958472)
Liver Int. 2006 Dec;26(10):1209-16. (PMID: 17105586)
Clin Gastroenterol Hepatol. 2008 Nov;6(11):1249-54. (PMID: 18995215)
Aliment Pharmacol Ther. 2012 Dec;36(11-12):1057-66. (PMID: 23066946)
World J Gastroenterol. 2007 Feb 14;13(6):837-44. (PMID: 17352011)
J Hepatol. 2012 Jun;56(6):1363-70. (PMID: 22314419)
Hepatology. 2006 Oct;44(4):865-73. (PMID: 17006923)
Hepatology. 2006 Jul;44(1):27-33. (PMID: 16799979)
Hepatology. 2006 Apr;43(4):682-9. (PMID: 16502396)
J Hepatol. 2014 Jan;60(1):167-74. (PMID: 23973932)
Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461)
Hepatology. 2009 Oct;50(4):1072-8. (PMID: 19585618)
Obes Surg. 2011 Apr;21(4):431-9. (PMID: 20532833)
Clin Chim Acta. 2012 Dec 24;414:154-7. (PMID: 22985537)
J Hepatol. 2011 Jun;54(6):1224-9. (PMID: 21145805)
Hepatology. 2012 Jun;55(6):2005-23. (PMID: 22488764)
Gastroenterology. 2003 Aug;125(2):437-43. (PMID: 12891546)
Hepatol Int. 2013 Mar;7(1):65-71. (PMID: 26201622)
- Accession Number:
0 (Biomarkers)
0 (Keratin-18)
0 (M30 cytokeratin-18 peptide, human)
0 (Peptide Fragments)
EC 2.3.2.2 (gamma-Glutamyltransferase)
EC 2.6.1.1 (Aspartate Aminotransferases)
EC 2.6.1.2 (Alanine Transaminase)
- Publication Date:
Date Created: 20140904 Date Completed: 20150526 Latest Revision: 20220311
- Publication Date:
20250114
- Accession Number:
PMC4153577
- Accession Number:
10.1371/journal.pone.0105903
- Accession Number:
25184298
No Comments.